Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers

NCT02991638 is registered in ClinicalTrials.gov with The University of Hong Kong as lead sponsor.

NCT NCT02991638
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02991638 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers
Lead sponsor
The University of Hong Kong
Phase
Phase 3
Overall status
Unknown status
Start date
November 1, 2016
Completion date
June 30, 2021
Enrollment
62 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b, chronic lymphocytic leukemia, follicular lymphoma, indolent b-cell lymphomas, lymphoma, small lymphocytic, mantle-cell lymphoma, waldenstrom's macroglobulinaemia